Clinical Data Inc

Clinical Data — Collins Stewart 4th Annual Growth Conference 2008

30 slides from Clinical Data's conference presentation, Jul 9, 2008

  1. Slide 1: Collins Stewart 4th Annual Growth Conference July 9, 2008

    Slide 1: Collins Stewart 4th Annual Growth Conference July 9, 2008

    1 Collins Stewart 4th Annual Growth Conference July 9, 2008 NASDAQ: CLDA

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Se

  3. Slide 3: Corporate Snapshot

    Slide 3: Corporate Snapshot

    Corporate Snapshot Headquarters Newton, MA NASDAQ CLDA 52 Week Price Range $12.85 to $28.90* Shares Outstanding 21.14M* Market Cap $290.25M* *As of market close on July 07, 2008 5

  4. Slide 4: Our Mission

    Slide 4: Our Mission

    Our Mission To improve the treatment of disease by commercializing proprietary predictive tests and targeted therapeutics leveraging genetic and other biomarkers that guide therapeutic response and the diagnosis and management of complex clinical conditions 7

  5. Slide 5: Clinical Data - Key Drivers

    Slide 5: Clinical Data - Key Drivers

    Clinical Data - Key Drivers Emerging genomics pure play with valuable intellectual property and expertise Proprietary genetic and pharmacogenetic tests Late stage drug candidate - Vilazodone: In Phase 3 of development for the treatment of depression 9

  6. Slide 6: Our Businesses

    Slide 6: Our Businesses

    Our Businesses Comprehensive Genomics Services Targeted Therapeutics Mainstream Clinical Care Patients Providers Payers Clinical Trials and Research Biotech/ Pharmaceutical Companies Proprietary Genetic and Pharmacogenetic Tests 11

  7. Slide 7: Targeted Therapeutic: Vilazodone

    Slide 7: Targeted Therapeutic: Vilazodone

    13 Targeted Therapeutic: Vilazodone

  8. Slide 8: Vilazodone Profile

    Slide 8: Vilazodone Profile

    Vilazodone Profile: Genetically guided, dual-acting serotonergic in development for the treatment of depression Unique dual mechanism of action: SSRI and 5HT1A partial agonist Status of development Positive results from the first Phase 3 study announced in 2007 In March 2008, initiated second Phase

  9. Slide 9: Vilazodone Phase 3 Study Results

    Slide 9: Vilazodone Phase 3 Study Results

    Vilazodone Phase 3 Study Results Achieved statistical significance on primary (MADRS) and related secondary endpoints of efficacy Vilazodone was generally safe and well-tolerated in this study Discontinuations were balanced between vilazodone and placebo The most common treatment-emergent adverse ev

  10. Slide 10: Proprietary Biomarker Identifies 30% of Patients with Higher Response

    Slide 10: Proprietary Biomarker Identifies 30% of Patients with Higher Response

    Proprietary Biomarker Identifies 30% of the Patients with a Higher than Average Response to Vilazodone Least square means of observed MADRS total score by week for Biomarker Vilazodone-treated patients who are marker positive have twice the change in MADRS at week 8 compared to the overall populatio

  11. Slide 11: Vilazodone Development Plan: Milestones

    Slide 11: Vilazodone Development Plan: Milestones

    Vilazodone Development Plan: Milestones Second registration Phase 3 study launched March 2008 Study expected to be completed in the first half of 2009 Long-term safety study launched December 2007 Closed enrollment 6 weeks ahead of schedule Manufacture of commercial supply proceeding NDA filing expe

  12. Slide 12: Vilazodone Is A Very Valuable Asset

    Slide 12: Vilazodone Is A Very Valuable Asset

    Vilazodone Is A Very Valuable Asset Vilazodone has been tested in over 1,000 patients and has demonstrated efficacy in the Phase 3 trial Statistical significance in change in MADRS at week 1 No difference between vilazodone and placebo on sexual function as measure by ASEX scale Other side effects w

  13. Slide 13: Genetic and Pharmacogenetic Tests

    Slide 13: Genetic and Pharmacogenetic Tests

    25 Genetic and Pharmacogenetic Tests

  14. Slide 14: Genetic Testing Landscape

    Slide 14: Genetic Testing Landscape

    Genetic Testing Landscape Direct-to-consumer Risk for disease Complex diseases with links to treatment Pharmacogenetic tests for drug prescription Examples Marketed by Whole Genome Scans Paternity Nutrition Disease Markers Prostate Cancer Parkinson's Disease Alzheimer's Disease Valuation by Payers L

  15. Slide 15: Expertise and proprietary markers of drug response

    Slide 15: Expertise and proprietary markers of drug response

    Expertise and proprietary markers of drug response Targeted drugs launched with companion pharmacogenetic tests Companion tests launched as companion or combination product Pharmacogenetic tests launched independently of associated drug Foundation Intellectual Property Developing Value Tools for Cli

  16. Slide 16: Genetic Biomarker Intellectual Property

    Slide 16: Genetic Biomarker Intellectual Property

    Genetic Biomarker Intellectual Property Diagnosis of complex diseases or syndromes FAMILION LQTS (Long QT Syndrome) Brugada Syndrome Related familial arrhythmogenic disorders Drug receptors FCGAMMA IIIA (IgG1 monoclonal antibodies) VKORC1 (warfarin) ADME genes Transport MDR1, OCT1, MRP1 (chemotherap

  17. Slide 17: FCGR3A and Efficiency of Cell Lysis

    Slide 17: FCGR3A and Efficiency of Cell Lysis

    FCGR3A Efficient Cell Lysis Inefficient Cell Lysis Dall'Ozzo S, Tartas S, Paintaud G, et al, Cancer Research, 64:4664-4669 FCGR3A 158 V/F or F/F FCGRIIIA Variant Affects Efficiency of Tumor Cell Lysis by IgG1 Mabs IgG1 Mab Tumor Cell 158 V/V NK Cell IgG1 Mab 33

  18. Slide 18: FCGR3A V158F in Response to IgG1 MABs

    Slide 18: FCGR3A V158F in Response to IgG1 MABs

    FCGR3A V158F is Proving Important in Response to IgG1 MABs Response to trastuzumab (Herceptin) in HER2/neu- positive metastatic breast cancer Response to cetuximab (Erbitux) in metastatic colorectal cancer Response to rituximab (Rituxan) monotherapy in follicular lymphoma Response to rituximab in Wa

  19. Slide 19: Genetic and Pharmacogenetic Tests - We Are Delivering

    Slide 19: Genetic and Pharmacogenetic Tests - We Are Delivering

    Genetic and Pharmacogenetic Tests - We Are Delivering (1) Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publications and resources. (1) Test Long Q/T Cardiology ~100,000 (U.S.) 1/3,000 Disease Incidence/ Prevalence Disease/Therapeutic Area ~2,000

  20. Slide 20: Payer Progress Since Last Update

    Slide 20: Payer Progress Since Last Update

    Progress since last update Approved Medicaid provider in 30 states covering ~29M lives Growing number of BCBS plans: ~65M PPO and ~15M HMO lives covered 15 direct account contracts with key hospital systems Positive coverage policies and contracting increasing with major private payers Payer lives e

  21. Slide 21: millions

    Slide 21: millions

    millions FY ‘07 FY ‘08 FY ‘09E CLINICAL & DATA A)

  22. Slide 22: The Genomics Services Company

    Slide 22: The Genomics Services Company

    The Genomics Services Company(tm)

  23. Slide 23: Cogenics Overview

    Slide 23: Cogenics Overview

    Overview High-quality sequencing, gene expression, genotyping and other molecular services worldwide Broad customer base, U.S. and international, including most of the top 20 pharmaceutical companies, Dovetails with next generation genomic testing for diagnostics and targeted drug therapy (companion

  24. Slide 24: Broadest genomics services menu in the industry

    Slide 24: Broadest genomics services menu in the industry

    Broadest genomics services menu in the industry: Sequencing ABI 3730 Roche 454 GS FLX (new) Genotyping RFLP Mapping Sequenom Luminex Illumina iScanTM System Agilent Microarray aCGH miRNA Affymetrix Microarray Whole Genome Association DNA Analysis DME-T Algynomics Pain Chip Gene Expression Analysis M

  25. Slide 25: Financials

    Slide 25: Financials

    ience Healthcar. Financials

  26. Slide 26: Fiscal 2008 Summary

    Slide 26: Fiscal 2008 Summary

    Fiscal 2008 Summary Revenue from continuing operations was up 20% PGxHealth revenue grew 33%; tests sales grew 41% Cogenics revenue grew 18% Cash burned for the first 9 months was ~$19.0M; $27.0M for the full year; average quarterly burn from operations was ~$7.0M Ramped fourth quarter spending in P

  27. Slide 27: Fiscal Year Revenue Growth

    Slide 27: Fiscal Year Revenue Growth

    Fiscal Year Revenue Growth $24.4 $20.6 $2.7 $29.4 $24.3 $4.6 FY '07 FY '08 $1.1 $0.5 53

  28. Slide 28: Fiscal Year 2009 Objectives

    Slide 28: Fiscal Year 2009 Objectives

    Fiscal Year 2009 Objectives Advance vilazodone development program with target NDA filing in late 2009 Drive adoption of the Company's proprietary genetic and pharmacogenetic tests Continue to advance priority drug response marker programs and acquire new proprietary markers Identify opportunities w

  29. Slide 29: Clinical Data - Key Drivers

    Slide 29: Clinical Data - Key Drivers

    Clinical Data - Key Drivers Emerging genomics pure play Proprietary genetic and pharmacogenetic tests Existing revenue base and pipeline of new tests Growing sales in FAMILION and PGxPredict Late stage drug candidate - Vilazodone Met primary and related secondary end points in first registration tri

  30. Slide 30: Thank You

    Slide 30: Thank You

    59 Thank You www.clda.com Investor inquiries: Dahlia Bailey 415-896-5862

Source: SEC EDGAR · 8-K filed Jul 9, 2008

More decks from Clinical Data Inc